HCA Healthcare, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by HCA Healthcare, Inc. on April 23, 2026. The filing was submitted on April 28, 2026. The document details the voting outcomes for director elections, auditor ratification, executive compensation, and stockholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Out of 223,568,966 shares outstanding, 209,777,472 shares were represented at the meeting. Key outcomes include:
- Director Elections: All nine nominees were elected. Notable voting patterns included significant "Against" votes for Nancy-Ann DeParle (22,234,733) and Hugh F. Johnston (15,858,336), while other directors received fewer than 10 million "Against" votes.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 192,731,533 votes in favor.
- Executive Compensation: The non-binding advisory resolution on named executive officer compensation was approved with 182,386,619 votes in favor.
- Stockholder Proposals: Two proposals were rejected: a report on healthcare consequences (21,156,498 for vs. 173,337,098 against) and a proposal regarding shareholders' right to act by written consent (42,842,519 for vs. 152,097,860 against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the elevated "Against" votes for directors Nancy-Ann DeParle and Hugh F. Johnston.
- Confirm the total number of shares outstanding (223,568,966) and the percentage of shares represented at the meeting (approximately 93.8%).
- Review the 2026 Proxy Statement for details on the rejected stockholder proposals regarding healthcare consequences and written consent rights.
- Note that the filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.